Skip to main content

Hodgkin Lymphoma News

News
01/17/2024
A 10-year trial follow-up indicated that the exclusion of involved-node radiotherapy was correlated with lower progression-free survival among ePET-negative patients with localized Hodgkin lymphoma.
A 10-year trial follow-up indicated that the exclusion of involved-node radiotherapy was correlated with lower progression-free survival among ePET-negative patients with localized Hodgkin lymphoma.
A 10-year trial follow-up...
01/17/2024
Oncology
News
07/08/2022
Researchers discuss strategies to manage classical Hodgkin lymphoma during the DTIC shortage and propose a treatment algorithm based on fitness and safety.
Researchers discuss strategies to manage classical Hodgkin lymphoma during the DTIC shortage and propose a treatment algorithm based on fitness and safety.
Researchers discuss strategies...
07/08/2022
Journal of Clinical Pathways
News
10/14/2020
Surveillance, early interventions, and treatment refinements may reduce mortality risks among high-risk subgroups in patients with classical Hodgkin lymphoma.
Surveillance, early interventions, and treatment refinements may reduce mortality risks among high-risk subgroups in patients with classical Hodgkin lymphoma.
Surveillance, early...
10/14/2020
Journal of Clinical Pathways
News
06/17/2020
A single institution study conducted at the Ospedale Oncologico di Riferimento Regionale (Italy) provided data on the cumulative incidence of secondary malignancies after treatment for Hodgkin lymphoma.
A single institution study conducted at the Ospedale Oncologico di Riferimento Regionale (Italy) provided data on the cumulative incidence of secondary malignancies after treatment for Hodgkin lymphoma.
A single institution study...
06/17/2020
Journal of Clinical Pathways
News
05/14/2020
In patients with relapsed or refractory classic Hodgkin lymphoma, pembrolizumab may be superior to brentuximab vedotin and provide statistically significant and clinically meaningful improvement in PFS across all subgroups.
In patients with relapsed or refractory classic Hodgkin lymphoma, pembrolizumab may be superior to brentuximab vedotin and provide statistically significant and clinically meaningful improvement in PFS across all subgroups.
In patients with relapsed or...
05/14/2020
Journal of Clinical Pathways